Loading...
Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer
The androgen receptor (AR) is widely expressed in breast cancer (BC) and evidence suggests dependence on AR signaling for growth and survival. AR antagonists such as enzalutamide and seviteronel have shown success in pre-clinical models and clinical trials of prostate cancer, and are currently being...
Na minha lista:
| Udgivet i: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5517319/ https://ncbi.nlm.nih.gov/pubmed/28468774 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0111 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|